Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Protalix Drug Set To Compete In Tough Gaucher Market Via Early Access Scheme

This article was originally published in The Pink Sheet Daily

Executive Summary

Both Protalix and Shire stand to benefit from Genzyme's Cerezyme shortage.
Advertisement

Related Content

Continued Genzyme Problems Offer Gaucher Opportunity To Competitors
Continued Genzyme Problems Offer Gaucher Opportunity To Competitors
Shire Files NDA For Gaucher Disease Drug With Data Showing Non-Inferiority To Cerezyme
Shire Files NDA For Gaucher Disease Drug With Data Showing Non-Inferiority To Cerezyme
Multiple Factors Suggest Genzyme Still Faces Problems Related To Cerezyme
Positive Phase III results for Shire's Gaucher drug Vela
Positive Phase III results for Shire's Gaucher drug Vela
Genzyme Plant Cleanup Brings Temporary Halt To Fabrazyme, Cerezyme Production
Genzyme Plant Cleanup Brings Temporary Halt To Fabrazyme, Cerezyme Production

Topics

Advertisement
UsernamePublicRestriction

Register

PS069850

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel